shRNA technology: investigating Ras-dependent cancer

Affiliations

Free article

Comment

Erica V Stein et al. Cancer Biol Ther. 2009 Oct.

Free article

. 2009 Oct;8(19):1798-9.

doi: 10.4161/cbt.8.19.9681.

¹ Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute/NIH, Bethesda, MD, USA.

No abstract available

Comment on

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. Scholl C, et al. Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017. Cell. 2009. PMID: 19490892
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. Luo J, et al. Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006. Cell. 2009. PMID: 19490893 Free PMC article.